You are here

Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn’s Disease: A Bayesian Network Meta-analysis.

Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn’s Disease: A Bayesian Network Meta-analysis. Inflamm Bowel Dis. 2017 Jan 31;: Authors: Coward S, Kuenzig ME, Hazlewood G, Clement F, McBrien K, Holmes R, Panaccione R, Ghosh S, Seow CH, Rezaie A, Kaplan GG Abstract BACKGROUND: Induction treatment of mild-to-moderate Crohn’s disease is controversial. PURPOSE: To compare the induction of remission between different doses of mesalamine, sulfasalazine, corticosteroids, and budesonide for active Crohn’s disease. DATA SOURCES: We identified randomized controlled trials from existing Cochrane reviews…

Read More

High Dietary Intake of Specific Fatty Acids Increases Risk of Flares in Patients with Ulcerative Colitis in Remission During Treatment With Aminosalicylates.

High Dietary Intake of Specific Fatty Acids Increases Risk of Flares in Patients with Ulcerative Colitis in Remission During Treatment With Aminosalicylates. Clin Gastroenterol Hepatol. 2017 Jan 18;: Authors: Barnes EL, Nestor M, Onyewadume L, De Silva P, Korzenik JR, DREAM Investigators Abstract BACKGROUND & AIMS: Dietary factors may have a significant role in relapse of disease among patients with ulcerative colitis (UC). However, the relationship between diet and UC is inadequately understood. We analyzed data from the diet’s role in exacerbations of mesalamine maintenance study to determine whether dietary…

Read More

The effects of aminosalicylates or thiopurines on the risk of colorectal cancer in inflammatory bowel disease.

Related Articles The effects of aminosalicylates or thiopurines on the risk of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther. 2016 Dec 19;: Authors: Carrat F, Seksik P, Colombel JF, Peyrin-Biroulet L, Beaugerie L, CESAME Study Group Abstract BACKGROUND: Whether aminosalicylates or thiopurines reduce the risk of colorectal cancer (CRC) in inflammatory bowel (IBD) disease is controversial. AIM: To assess simultaneously the chemopreventive effect of aminosalicylates or thiopurines in a case-control study nested in the CESAME observational cohort that enrolled consecutive patients with IBD between May 2004 and June…

Read More

Once- Versus Twice-daily Mesalazine to Induce Remission in Paediatric Ulcerative Colitis: A Randomised Controlled Trial.

Related Articles Once- Versus Twice-daily Mesalazine to Induce Remission in Paediatric Ulcerative Colitis: A Randomised Controlled Trial. J Crohns Colitis. 2016 Oct 3;: Authors: Turner D, Yerushalmi B, Kori M, Broide E, Mozer-Glassberg Y, Shaoul R, Kolho KL, Shteyer E, Shamaly H, Ledder O, Cohen S, Peleg S, On A, Levine A Abstract BACKGROUND: Trials in adults suggested that, in ulcerative colitis [UC], once-daily [OD] dosing of 5-ASA [5-amino salicylic acid] may be as or more effective than twice-daily [BD] dosing. In this induction of remission, investigator-blinded, randomised controlled-trial, we…

Read More

5-aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine.

Related Articles 5-aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine. Inflamm Bowel Dis. 2006 Apr;12(4):251-7 Authors: Hande S, Wilson-Rich N, Bousvaros A, Zholudev A, Maurer R, Banks P, Makrauer F, Reddy S, Burakoff R, Friedman S Abstract BACKGROUND: Small uncontrolled trials have suggested that 5-aminosalicylate (5-ASA) medications increase 6-thioguanine nucleotide (6-TGn) levels in adults with Crohn’s disease (CD) on azathioprine (AZA) or 6-mercaptopurine (6-MP), presumably through the inhibition of thiopurine methyltransferase (TPMT). We tested the theory…

Read More

Review article: evolutionary advances in the delivery of aminosalicylates for the treatment of ulcerative colitis.

Related Articles Review article: evolutionary advances in the delivery of aminosalicylates for the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2006 Aug 1;24(3):465-74 Authors: Cohen RD Abstract Ulcerative colitis is a chronic and debilitating disease that involves inflammation of the colonic mucosa. Current therapies aim to reduce the symptom burden of ulcerative colitis and maintain disease quiescence. The standard first-line treatment for mild-to-moderate ulcerative colitis is 5-aminosalicylate therapy, which is available in oral and rectal (topical) formulations. While current 5-aminosalicylate formulations are effective in the majority of patients, they are…

Read More

The metabolism of mesalamine and its possible use in colonic diverticulitis as an anti-inflammatory agent.

Related Articles The metabolism of mesalamine and its possible use in colonic diverticulitis as an anti-inflammatory agent. J Clin Gastroenterol. 2006 Aug;40 Suppl 3:S150-4 Authors: Cohen HD, Das KM Abstract 5-Aminosalicylic acid (5-ASA) is the mainstay of therapy for inflammatory bowel disease (IBD), particularly ulcerative colitis. 5-ASA is the active moiety in sulfasalazine, which was initially developed for the treatment of rheumatoid arthritis more than 60 years ago, by linking 5-ASA with sulfapyridine Because many of the side effects related to sulfasalazine were found to be due to sulfapyridine, several…

Read More

Oral mesalamine and clinical remission are associated with a decrease in the extent of long-standing ulcerative colitis.

Related Articles Oral mesalamine and clinical remission are associated with a decrease in the extent of long-standing ulcerative colitis. Inflamm Bowel Dis. 2006 Jul;12(7):537-42 Authors: Picco MF, Krishna M, Cangemi JR, Shelton D Abstract OBJECTIVE: To compare colonoscopy alone with surveillance biopsy for the determination of anatomic extent in long-standing ulcerative colitis (UC). To assess the influences of mesalamine use and clinical disease activity on the change of histologic extent with time. MATERIALS AND METHODS: Disease extent (proctosigmoiditis, left-sided colitis, or pancolitis) measured by colonoscopy and surveillance biopsy was compared…

Read More

Review article: the effect of aminosalicylates and immunomodulation on cancer risk in inflammatory bowel disease.

Related Articles Review article: the effect of aminosalicylates and immunomodulation on cancer risk in inflammatory bowel disease. Aliment Pharmacol Ther. 2006 Oct;24 Suppl 3:64-7 Authors: Stange EF Abstract Ulcerative colitis and, maybe to a similar extent, Crohn’s disease are associated with an increased risk of colorectal carcinoma. As a consequence of this increased risk, surveillance strategies have been proposed to prevent colorectal carcinoma through early detection of dysplasia, which may herald malignant disease. These surveillance strategies are controversial for several reasons discussed in this review. It may be concluded from…

Read More

Review article: aminosalicylates for distal colitis.

Related Articles Review article: aminosalicylates for distal colitis. Aliment Pharmacol Ther. 2006 Oct;24 Suppl 3:41-4 Authors: Gionchetti P, Rizzello F, Morselli C, Tambasco R, Campieri M Abstract About two-thirds of patients with ulcerative colitis have an inflammatory involvement distal to the splenic flexure and therefore may be effectively treated with topical treatment. This allows the delivery of the active drug directly to the site of inflammation, limiting the systemic absorption and the potential side effects. Topical aminosalicylate therapy is the most effective approach, provided that the formulation reaches the upper…

Read More
<< Go Back